Vulnerable premature babies needing extra protection against RSV will receive a long-lasting single injection of nirsevimab, ...

The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

Despite near universal availability of nirsevimab, only 35% of eligible children receive nirsevimab for RSV prophylaxis.

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial virus prophylaxis, with uptake varying by race and other social factors.

John Stewart, Director of Specialised Commissioning at NHS England said: “For babies born very prematurely, the risk of ...

Babies born very prematurely or at high risk in Northern Ireland are set to benefit from enhanced protection against ...

Vulnerable premature babies who need extra protection against RSV may receive six months’ protection in a long-lasting single ...

BABIES born very prematurely in Northern Ireland will be offered a single long-acting injection against respiratory syncytial ...

Babies born very prematurely will be offered protection against respiratory syncytial virus (RSV) with a long-acting antibody ...

Dr Reddy's Laboratories reported a 1.4% increase in consolidated net profit to ₹1,409 crore for Q1FY26, compared to ₹1,392 ...